Pediatr. praxi. 2010;11(5):282-286

What should the paediatrician know about precocious puberty

doc.MUDr.Marta Šnajderová, CSc., RNDr.Daniela Zemková, CSc.
Pediatrická klinika 2. LF UK a FN Motol, Praha

Evaluation of sexual development is an integral part of everyday practice of pediatrician. It is therefore essential that the practitioner

for children and adolescents knew the criteria of normal and abnormal onset of puberty. Precocious puberty may be a variant of normal

development, but may also be an expression of a serious disease that requires early and detailed examination by a specialist. Diagnostics

of precocious puberty is an interdisciplinary, coordinated by children’s endocrinologist. The goal of treatment is to bring a child’s development

of its peers in terms of sexual development, growth and psyche. The publication presents an analysis of various forms of precocious

puberty, a brief overview of diagnostic and therapeutic approaches.

Keywords: precocious puberty, therapy, gonadoliberin analogs, growth and development, final height

Published: October 15, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šnajderová M, Zemková D. What should the paediatrician know about precocious puberty. Pediatr. praxi. 2010;11(5):282-286.
Download citation

References

  1. Winter JS, Faiman C, Hobson WC, et al. Pituitary - gonadal relations in infancy. I. Patterns of serum gonadotropin concentrations from birth to four years of age in man and chimpanzee. J Clin Endocrinol Metab. 1975; 40: 545-551. Go to original source... Go to PubMed...
  2. Apter D, Butzov TL, Laughlin GA, et al. Gonadotropin releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal pattern of circulating gonadotropins. J Clin Endocrinol Metab. 1993; 76: 940-949. Go to original source...
  3. Zemková D, Šnajderová M. Puberta v ambulanci pediatra. Pediatrie pro praxi 2009; 10(5): 289-293.
  4. Šnajderová M, Zemková D. Předčasná puberta. Praha: Galén; 2000.
  5. Mitsushima D, Hei DL, Terasawa E. Gamma-aminobutyric acid is an inhibitory neurotransmitter restricting the release of gonadotropin releasing hormone before the onset of puberty. Proceeding of the national Academy of Sciences of the USA; 1994; 91: 395-399. Go to original source... Go to PubMed...
  6. Gianetti E, Seminara S. Kisspeptin and KISS1R: a critical pathway in the reproductive system. Reproduction 2008; 136: 295-301. Go to original source... Go to PubMed...
  7. Bláha P, Krejčovský L. Somatický vývoj českých dětí. Semilongitudinální studie. Praha: PřFUK a SZÚ; 2006: 345.
  8. Tanner JM, Healy MJ, et al. Assessment of skeletal maturity and prediction of adult height (TW3 method). London: Saunders; 2001: 101.
  9. Kaplowitz PB, Oberfield SE, et al. Reexamination of the age limit for Defining when Puberty is Precocious in Girls in the United States: Implication for Evaluation and Treatment. Pediatrics 1999; 104: 936-941. Go to original source... Go to PubMed...
  10. DeVries L, Guz-Mark A, Lazar L, et al. Premature thelarche: Age at presenatation affects clinical course but not clinical characteristics or risk to progress to precocious puberty. The Journal of Pediatrics 2010; 156(3): 466-471. Go to original source... Go to PubMed...
  11. Chiabotto P, Costante L, de Sanctis C. Premature thelarche and environmental pollutants. Minerva Med 2006; 97(3): 277-285. Go to PubMed...
  12. de Vries L, Horev G, Schwartz M, et al. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol, 2006; 154(6): 891-898. Go to original source... Go to PubMed...
  13. Crowley WF, Comite F, Vale WW, et al. Therapeutic use of pituitary desenzitization with long-acting LHRH agonist: a potential new treatment of idiopathic precocious puberty. J Clin Endocrinol Metab, 1981; 52: 370-372. Go to original source... Go to PubMed...
  14. Magiakou MA, Manousaki D, Papadaki M, et al. The Efficacy and Safety of Gonadotropin-Releasing Hormone Analog Treatment in Childhood and Adolescence: A Single Center, Long-Term Follow-Up Study. J Clin Endocrinol Metab, 2010; 95: 109-117. Go to original source... Go to PubMed...
  15. Šnajderová M, Zemková D, Teslík L, et al. Hormonal suppression and sexual development in children with central precocious puberty in the first treatment cycle 12 weeks after injection of triptoreline 11.25 mg (Diphereline S. R. 11.25 mg): a pilot study. Ceska Gynekol, 2005; 70(2): 107-113.
  16. Isaac H, Patel L, Meyer S, Hall CM, et al. Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res. 2007; 68(4): 157-163. Go to original source... Go to PubMed...
  17. Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol, 2009, Article ID 812517, 4 pages. Go to original source... Go to PubMed...
  18. Wit JM, Balen HV, Kamp GA, et al. Of postponing normal puberty for improving final height. Eur J Endocrinol, 2004; 151(Suppl 1): S41-45. Go to original source... Go to PubMed...
  19. Ben-Haroush A, Goldberg-Stern H, Phillip M, de Vries L. GnRH agonist treatment in girls with precocious puberty does not compromise post-pubertal uterine size. Hum Reprod, 2007; 22(3): 895-900. Go to original source... Go to PubMed...
  20. Eugster EA. Peripheral precocious puberty: causes and current management. Horm Res, 2009; 71(Suppl 1): 64-67. Go to original source... Go to PubMed...
  21. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis, 2008; 19: 1-12. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.